2021
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reduction
2018
2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
Anderson E, Lopman B, Yi J, Yildirim I, Creech C, El-Khorazaty J, Shane A, Edwards K. 2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination. Open Forum Infectious Diseases 2018, 5: s675-s676. PMCID: PMC6255677, DOI: 10.1093/ofid/ofy210.1933.Peer-Reviewed Original ResearchGeometric mean titersAntibiotic exposureLogistic regression modelsRV vaccinesMultivariable logistic regression modelConcomitant antibiotic useRV immunizationLast doseVaccine doseVaccine groupImmunized childrenPrimary outcomeRotavirus immunizationAntibiotic administrationMean titersRegression modelsVaccine dosesSerological responseTreatment allocationAntibiotic useInclusion criteriaVaccine studiesImmune responseTreatment groupsSeroresponses